GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Price-to-Funds-From-Operations

Spexis AG (XSWX:SPEX) Price-to-Funds-From-Operations : (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Spexis AG (XSWX:SPEX) Business Description

Industry
Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.